2021年-2022年脑梗死阿替普酶溶栓患者住院人次及住院费用因素分析

Analysis of the number of hospitalizations and hospitalization cost factors in Alteplase Thrombolysis-Treated Cerebral Infarction Patients from 2021 to 2022

目的分析住院费用影响因素,为本地区急性脑梗死的预防及治疗提供参考,为减轻该类患者经济负担提供依据。方法以某院2021年1月1日-2022年12月31日神经内科阿替普酶静脉溶栓的急性脑梗死患者住院费用数据为依据,计数资料用卡方检验,对本次住院费用的影响因素进行多元逐步回归分析。结果阿替普酶溶栓患者占急性脑梗死患者的9.98%;溶栓患者年龄分布上60岁~79岁最多,30岁~39岁组最少;性别分布上男性68.88%,女性31.12%;溶栓总有效率73.4%;溶栓患者平均住院日为7.44±5.99天;溶栓患者次均费用16808.21±13931.39元。结论住院天数、疗效、溶栓后的合并症或并发症、年龄、性别是影响住院总费用的因素,应采取相应措施,控制平均住院日的同时降低转院、退院率,有效提升溶栓的有效率,从而控制溶栓治疗的费用,减轻急性脑梗死患者的经济负担。

Objectives This study aims to analyze factors affecting hospitalization costs,so as to provide a reference for the prevention and treatment of acute cerebral infarction in the region and provide a basis for reducing the economic burden of such patients.Methods The hospitalization cost data for patients with acute cerebral infarction who underwent alteplase intravenous thrombolysis in the Department of Neurology from January 1,2021,to December 31,2022,in a certain hospital were utilized.The enumeration data were analyzed using a chi-square test,and multiple stepwise regression analysis was performed on the influencing factors of hospitalization expenses.Results Alteplase thrombolysis patients accounted for 9.98%of patients with acute cerebral infarction.When considering the age distribution of thrombolysis patients,the majority falled between 60 and 79 years old,while the fewest were in the 30 to 39-year-old group.The gender distribution showed that 68.88%were male and 31.12%were female.The total effective rate of thrombolysis was 73.4%.The average length of stay for patients with thrombolysis was 7.44±5.99 days,with an average cost per time of 16808.21±13931.39 yuan.Conclusions The length of hospitalization,efficacy,complications or complications after thrombolysis,age,and gender are factors that affect the total hospitalization cost.Corresponding measures should be implemented to control the average length of stay,reduce transfer and discharge rates,and enhance the efficiency of thrombolysis.This will help control the cost of thrombolytic treatment and alleviate the economic burden on patients with acute cerebral infarction.